Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Bluejay Diagnostics (BJDX) EBITDA (2022 - 2023)

Bluejay Diagnostics' EBITDA history spans 2 years, with the latest figure at -$2.4 million for Q4 2023.

  • On a quarterly basis, EBITDA rose 2.73% to -$2.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$10.3 million, a 10.66% decrease, with the full-year FY2025 number at -$7.0 million, up 3.02% from a year prior.
  • EBITDA hit -$2.4 million in Q4 2023 for Bluejay Diagnostics, down from -$2.3 million in the prior quarter.
  • Over the last five years, EBITDA for BJDX hit a ceiling of -$2.0 million in Q2 2022 and a floor of -$2.9 million in Q2 2023.